Los consumidores de té podrían tener un mejor control del azúcar en sangre
MIÉRCOLES, 4 de octubre de 2023 (HealthDay News) – Beber té oscuro diariamente podría ayudar a equilibrar los niveles de azúcar en sangre y prevenir la diabetes tipo 2, la forma de la enfermedad más estrechamente relacionada con la obesidad.Este es el…
Learn MoreDurable Reductions in HbA1c, Body Weight Seen With Semaglutide
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — Use of once-weekly subcutaneous semaglutide is associated with sustained reductions in hemoglobin A1c (HbA1c) and body weight, according to a study presented at the annual meeting of the European Association…
Learn MoreApp Can Accurately Detect Autism in Young Children
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — An autism screening digital application (app) administered to young children can accurately detect autism, according to a study published online Oct. 2 in Nature Medicine.Sam Perochon, from Duke University i…
Learn MoreSeniors With ADHD Face Higher Car Crash Risk
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — While studies of ADHD and driving usually target teens, a new one focused on seniors found they have a significantly higher risk of car crashes.Older adults with attention-deficit/hyperactivity disorder (ADH…
Learn MoreED Visits Up for Eating Disorders Across All Ages During Pandemic
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — During the pandemic, there was an increase in emergency department visits for eating disorders among adolescents, young adults, and older adults, while hospital admissions only increased for adolescents, acc…
Learn MoreNirmatrelvir/Ritonavir Cuts COVID-19 Complications in Highest-Risk Patients
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — For individuals with the highest risk for complications from COVID-19 infection, nirmatrelvir and ritonavir is associated with a reduced risk for COVID-19 hospitalization or death, according to a study publi…
Learn MoreIn-Hospital Mortality Evaluated for SARS-CoV-2-Linked Sepsis
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — From March 2020 to November 2022, there was a decline in crude in-hospital mortality for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated sepsis, according to a study published online …
Learn MoreNeighborhood, Individual Factors Cut Racial Disparities in Heart Health
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — Neighborhood- and individual-level factors attenuate racial disparities in cardiovascular health, according to a study published online Sept. 29 in JAMA Network Open.Anika L. Hines, Ph.D., M.P.H., from the V…
Learn MoreGemcitabine, Cisplatin, Nivolumab Facilitate Bladder Sparing
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — For patients with muscle-invasive bladder cancer (MIBC), treatment with gemcitabine, cisplatin, plus nivolumab facilitates bladder sparing, according to a study published online Oct. 2 in Nature Medicine.
Matthew D. Galsky, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a phase 2 study of 76 patients with MIBC who received four cycles of gemcitabine, cisplatin, plus nivolumab followed by clinical restaging. Patients who achieved a clinical complete response (cCR) could proceed without cystectomy.
Of the patients, 33 achieved a cCR (43 percent); 32 of the 33 opted to forgo immediate cystectomy. The researchers found that the positive predictive value of cCR for a composite outcome of two-year metastasis-free survival in patients forgoing immediate cystectomy or ATM, RB1, FANCC, and ERCC2) or increased tumor mutational burden. There was an association noted between the baseline and on-treatment immune contexture with clinical outcomes.
“Treatment for muscle-invasive bladder cancer is in need of major improvements from both a quality-of-life and an effectiveness standpoint,” Galsky said in a statement. “If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer.”
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Learn MoreCeftobiprole Noninferior to Daptomycin for Complicated Staph Infection
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — For patients with complicated Staphylococcus aureus bacteremia, ceftobiprole is noninferior to daptomycin for overall treatment success, according to a study published online Sept. 27 in the New England Jour…
Learn More